

DEU 3 mg QOD 0.24 (0.09,0.65)	DEU 3 mg QD 0.13 (0.05,0.35)	DEU 3 mg BID 0.14 (0.05,0.36)	DEU 3 mg BID 0.56 (0.36,0.88)	DEU 6 mg BID 1.03 (0.75,1.43)	DEU 6 mg BID 0.58 (0.37,0.91)	DEU 6 mg BID 1.03 (0.75,1.43)	DEU 12 mg QD 0.89 (0.65,1.21)	DEU 12 mg QD 0.89 (0.65,1.21)	DEU 6 mg QD 1.79 (1.06,25.3)	DEU 6 mg QD 0.95 (0.32,2.87)	BRE 30 mg QD 5.19 (1.06,25.3)	ROP 50 mg QD 1.91 (0.39,9.4)	ROP 100 mg QD 0.20 (0.05,0.8)	ROP 200 mg QD 0.13 (0.03,0.5)	ROP 400 mg QD 0.64 (0.43,0.95)	TOF 2 mg BID 1.09 (0.38,3.13)	TOF 5 mg BID 1.71 (0.61,4.76)	TOF 10 mg BID 0.63 (0.34,1.16)	TOF 15 mg BID 0.69 (0.62,0.77)	TOF 15 mg BID 0.86 (0.56,1.33)	TOF 15 mg BID 0.60 (0.39,0.91)	SOL 100 mg BID 1.48 (0.08,28.7)	SOL 200 mg BID 1.71 (0.09,34.2)	SOL 400 mg BID 0.59 (0.15,2.38)	SOL 400 mg BID 0.47 (0.19,1.17)	BAR 2 mg QD 10.00 (0.53,190.4)	BAR 4 mg QD 1.00 (0.48,2.0)	BAR 8 mg QD 0.67 (0.39,1.1)	BAR 10 mg QD 0.78 (0.51,1.2)	MTX 0.73 (0.56,0.9)	CSP 0.56 (0.27,1.1)	APR 30 mg BID 0.41 (0.21,0.8)	FUM 1.72 (1.27,5.0)	PB 1.47 (0.43,5.0)		
0.14 (0.05,0.36)	0.56 (0.36,0.88)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)	1.03 (0.75,1.43)

Table 4. League table of PASI-75 at 12-16 weeks. The results was assessed through the column header treatment compared with the reference row treatment.